Royalty Pharma PLC $RPRX Shares Purchased by Inceptionr LLC

Inceptionr LLC raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 287.2% during the first quarter, HoldingsChannel reports. The fund owned 44,557 shares of the biopharmaceutical company’s stock after acquiring an additional 33,050 shares during the quarter. Royalty Pharma comprises approximately 0.5% of Inceptionr LLC’s holdings, making the stock its 11th largest position. Inceptionr LLC’s holdings in Royalty Pharma were worth $2,137,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Lido Advisors LLC bought a new stake in shares of Royalty Pharma in the 1st quarter worth about $924,000. Cetera Investment Advisers lifted its position in shares of Royalty Pharma by 7.2% during the first quarter. Cetera Investment Advisers now owns 76,916 shares of the biopharmaceutical company’s stock worth $3,690,000 after purchasing an additional 5,180 shares during the last quarter. NewEdge Wealth LLC acquired a new position in Royalty Pharma in the first quarter worth about $533,000. CI Investments Inc. grew its stake in Royalty Pharma by 154.8% in the first quarter. CI Investments Inc. now owns 173,663 shares of the biopharmaceutical company’s stock worth $8,331,000 after purchasing an additional 105,516 shares in the last quarter. Finally, ABN Amro Investment Solutions bought a new stake in Royalty Pharma in the first quarter valued at about $1,541,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Royalty Pharma news, EVP Marshall Urist sold 9,099 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total value of $508,452.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $56.52, for a total transaction of $5,652,000.00. Following the transaction, the executive vice president directly owned 459,399 shares of the company’s stock, valued at approximately $25,965,231.48. This trade represents a 17.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 427,800 shares of company stock valued at $23,333,723 over the last three months. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $59.02 on Friday. The company has a market cap of $33.99 billion, a P/E ratio of 40.15, a PEG ratio of 10.40 and a beta of 0.43. The business has a 50 day moving average of $55.48 and a two-hundred day moving average of $49.14. Royalty Pharma PLC has a 52 week low of $34.08 and a 52 week high of $59.44. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $630.58 million for the quarter, compared to analysts’ expectations of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. As a group, analysts anticipate that Royalty Pharma PLC will post 5.18 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 annualized dividend and a yield of 1.6%. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Analyst Ratings Changes

A number of research firms have commented on RPRX. Weiss Ratings downgraded Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. TD Cowen upped their price target on Royalty Pharma from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Citigroup raised their price objective on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $56.57.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.